Acetaminophen - Generic Drug Details

What are the generic drug sources for acetaminophen and what is the scope of freedom to operate?

Acetaminophen is the generic ingredient in one hundred and eight branded drugs marketed by Ortho Mcneil Pharm, Rising, Aspiro, B Braun Medical, Baxter Hlthcare Corp, Caplin, Eugia Pharma, Fresenius Kabi Usa, Gland, Hikma, Inforlife, Mylan, Sandoz, Wockhardt Bio Ag, Zydus Pharms, Mallinckrodt Hosp, Cosette, Able, Acino Prods, Perrigo New York, Taro, Polymedica, J And J Consumer Inc, Aurobindo Pharma, Granules, Heritage, Marksans Pharma, Ohm Labs, Perrigo, Sun Pharm Inds Ltd, Kenvue Brands, Aurobindo Pharma Ltd, Haleon Us Holdings, Mikart, Scherer Labs, Zevra Therap, Forest Pharms, Mallinckrodt, Dr Reddys Labs Sa, Valeant, Dunhall, Pharmobedient, Alvogen, Anda Repository, Halsey, Lgm Pharma, Ne Rx Pharma, Quagen, Senores Pharms, Watson Labs, Mayrand, Shire, Aurolife Pharma Llc, Gilbert Labs, Graham Dm, Key Therap, Lannett Co Inc, Novast Labs, Nuvo Pharms Inc, Us Chem, Genus, Abhai Llc, Actavis Labs Ut Inc, Hikma Pharms, Mirror Pharms Llc, Nesher Pharms, Specgx Llc, Strides Pharma, Strides Pharma Intl, Sun Pharm Industries, Vintage Pharms, Hikma Intl Pharms, Wraser Pharms Llc, Pharm Res Assoc, Leitner Pharms, Boca Pharma Llc, West-ward Pharm Corp, Novartis, Teva, Robins Ah, Solvay, Actavis Mid Atlantic, Chartwell, Chartwell Molecular, Dava Pharms Inc, Genus Lifesciences, Pai Holdings, Valeant Pharms Llc, Am Therap, Amneal Pharms Ny, Ani Pharms, Duramed Pharms Barr, Elite Labs Inc, Everylife, Fosun Pharma, Hibrow Hlthcare, Kv Pharm, Lederle, Mutual Pharm, Puracap Pharm, Purepac Pharm, Rhodes Pharms, Roxane, Superpharm, Usl Pharma, Valeant Pharm Intl, Vitarine, Warner Chilcott, Watson Labs Florida, Whiteworth Town Plsn, Carnrick, Glaxosmithkline, Vangard, Janssen Pharms, Schering Plough, Cent Pharms, Ivax Pharms, Mallinckrodt Inc, Pharm Assoc, Tris Pharma Inc, Wes Pharma Inc, Cypress Pharm Inc, Ucb Inc, Ascher, Actavis Labs Fl Inc, Amneal Pharms, Apil, Ascent Pharms Inc, Barr, Caraco, Epic Pharma Llc, Novel Labs Inc, Ph Health, Prinston Inc, Ranbaxy, Ranbaxy Labs Ltd, Sanaluz, Sun Pharm Inds Inc, Upsher Smith Labs, Vintage Pharms Llc, Abana, Abbott, Abbvie, Bionpharma, Dr Reddys, Glenmark Pharms Ltd, L Perrigo Co, Lnk Intl Inc, Aft Pharms Us, Actavis Elizabeth, Sankalp Lifecare, Bristol Myers Squibb, Endo Operations, Gavis Pharms, Sanofi Aventis Us, Aaipharma Llc, Xanodyne Pharm, Cornerstone, Ivax Sub Teva Pharms, Mirror Pharms, Mylan Pharms Inc, Wockhardt Ltd, Alkem Labs Ltd, Chartwell Rx, Graviti Pharms, Macleods Pharms Ltd, Micro Labs Ltd India, Mpp Pharma, and Zydus Pharms Usa Inc, and is included in five hundred and thirty-three NDAs. There are thirty-one patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Acetaminophen has twenty-one patent family members in thirteen countries.

There are sixty-six drug master file entries for acetaminophen. Ninety-seven suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for acetaminophen

International Patents:	21
US Patents:	31
Tradenames:	108
Applicants:	169
NDAs:	533
Drug Master File Entries:	66
Finished Product Suppliers / Packagers:	97
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	1,433
Patent Applications:	7,093
Drug Prices:	Drug price trends for acetaminophen
Drug Sales Revenues:	Drug sales revenues for acetaminophen
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for acetaminophen
What excipients (inactive ingredients) are in acetaminophen?	acetaminophen excipients list
DailyMed Link:	acetaminophen at DailyMed

See drug prices for acetaminophen

See drug sales revenues for acetaminophen

Recent Clinical Trials for acetaminophen

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institutes of Health (NIH)	PHASE1
Brigham and Women's Hospital	PHASE1
AdventHealth	PHASE3

See all acetaminophen clinical trials

Generic filers with tentative approvals for ACETAMINOPHEN

Applicant	Application No.	Strength	Dosage Form
		325MG; 7.5MG	TABLET, EXTENDED RELEASE;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Medical Subject Heading (MeSH) Categories for acetaminophen

Analgesics, Non-Narcotic

Antipyretics

Paragraph IV (Patent) Challenges for ACETAMINOPHEN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
OFIRMEV	Injection	acetaminophen	650 mg/65 mL (10 mg/mL)	022450	1	2024-07-31
OFIRMEV	Injection	acetaminophen	1000 mg/100 mL (10 mg/mL)	022450	1	2011-04-07

US Patents and Regulatory Information for acetaminophen

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Granules	OXYCODONE AND ACETAMINOPHEN	acetaminophen; oxycodone hydrochloride	TABLET;ORAL	211708-001	Oct 31, 2019	AA	RX	No	No
Wes Pharma Inc	OXYCODONE AND ACETAMINOPHEN	acetaminophen; oxycodone hydrochloride	TABLET;ORAL	207510-003	Mar 21, 2018	AA	RX	No	No
Mallinckrodt	ANEXSIA 7.5/650	acetaminophen; hydrocodone bitartrate	TABLET;ORAL	089725-001	Sep 30, 1987		DISCN	No	No

Expired US Patents for acetaminophen

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Mallinckrodt Hosp	OFIRMEV	acetaminophen	SOLUTION;INTRAVENOUS	022450-001	Nov 2, 2010	6,028,222*PED
Kenvue Brands	TYLENOL	acetaminophen	TABLET, EXTENDED RELEASE;ORAL	019872-001	Jun 8, 1994	4,968,509
Kenvue Brands	TYLENOL	acetaminophen	TABLET, EXTENDED RELEASE;ORAL	019872-001	Jun 8, 1994	4,820,522

International Patents for acetaminophen

Country	Patent Number	Title	Estimated Expiration
Portugal	2421522
Japan	2011503198
Spain	2564547

Market Dynamics and Financial Trajectory for Acetaminophen

Last updated: February 19, 2026

What Are the Current Market Size and Key Drivers?

The global acetaminophen (paracetamol) market was valued at approximately $4.8 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 3.1% from 2023 to 2030, reaching an estimated $6.2 billion.

Key drivers include:

• High demand for over-the-counter (OTC) analgesics and antipyretics.
• Increased prevalence of pain and fever conditions, especially among aging populations and in developing regions.
• Expanding use in combination therapies for cold and flu remedies.

Market segmentation by application reveals:

• Pain management accounts for roughly 60% of sales.
• Fever reduction contributes to 30%.
• Other uses, such as in pediatric formulations and combination drugs, constitute the remaining 10%.

Regional markets display differing growth:

• North America presides with a 40% market share, driven by high healthcare spending and OTC drug consumption.
• Asia-Pacific shows the fastest growth rate at 4.2%, propelled by population size, rising healthcare infrastructure, and increasing OTC drug access.

How Does Regulatory Environment Influence Market Trends?

Regulatory policies significantly impact acetaminophen sales and R&D investments:

• The U.S. Food and Drug Administration (FDA) enforces dosage limits due to hepatotoxicity risks, capping individual doses at 650 mg for OTC formulations.
• The European Medicines Agency (EMA) restricts maximum daily doses for adults to 4 grams.
• Canada recommends a maximum of 3 grams per day for adults to reduce liver injury risk.

These regulations influence product formulations, limit high-dose offerings, and limit the development of concentrated formulations. They also prompt innovation in combination products with lower individual doses.

What Are the Key Competitive Landscape Features?

Primary companies dominate the market:

Company	Market Share (2022)	Notable Launches/Initiatives
Johnson & Johnson	25%	Introduction of new pediatric formulations
Bayer	20%	Expansion into combination cold remedies
Purdue Pharma	15%	Focus on low-dose formulations to meet regulatory standards
Others	40%	Multiple regional players with niche market shares

Patent expirations for several formulations between 2020 and 2025 open opportunities for generics. This has led to intensified price competition and increased reliance on brand differentiation through packaging, delivery methods, and combination therapies.

What Are the R&D and Innovation Trends?

Research focuses on:

• Safer delivery systems, such as extended-release formulations.
• Combining acetaminophen with other analgesics or anti-inflammatory agents to enhance efficacy.
• Developing lower hepatotoxicity profiles.
• Exploring alternative routes of administration, including transdermal patches and intranasal sprays.

Despite a mature market, innovation efforts aim to:

• Address safety concerns related to overdose and liver toxicity.
• Expand indications to include chronic pain and other conditions.

How Do Supply Chain Factors Affect the Market?

Supply chain stability is crucial:

• Raw material sourcing remains stable, with phenol derivatives being the primary precursor.
• Manufacturing disruptions have occurred during the COVID-19 pandemic but recovered by late 2021.
• Regulatory compliance and quality standards remain high, with batch testing and validation processes adding to costs.

Pricing is sensitive to raw material costs, exchange rates, and geopolitical stability in manufacturing countries.

What Is the Financial Outlook?

Profitability for manufacturers depends mainly on:

• Volume sales driven by OTC demand.
• Cost control in manufacturing, supply chain management.
• Strategic marketing to differentiate products amid generic competition.

The average selling price (ASP) for branded products remains higher than generics, but increasing generic penetration pressures margins.

Forecasts show a gradual decline in ASPs due to generic competition, offset somewhat by gains in emerging markets and innovation-driven premium products.

Key Takeaways

• The global acetaminophen market is mature, with steady growth driven by OTC demand and regional healthcare expansion.
• Regulatory restrictions influence product formulations, R&D efforts, and market entry strategies.
• Major players are competing on innovation, safety profiles, and regional expansion, with patent expirations opening the gates for generics.
• Supply chains recovered from pandemic disruptions, supporting stable availability.
• Financial performance hinges on balancing volume growth with pricing pressures and R&D investments in safety and new delivery methods.

FAQs

How are regulatory changes affecting acetaminophen formulations?

Regulations impose dose caps to minimize liver toxicity, restricting high-dose product development. Companies shift toward lower-dose formulations and combination therapies to comply and meet consumer needs.

What are the main patent expiration dates affecting the market?

Major patents for branded formulations expired between 2020 and 2025, enabling aggressive price competition from generics and branded generics.

Which regions show the fastest market growth?

Asia-Pacific exhibits the highest CAGR at approximately 4.2%, driven by rising healthcare infrastructure and demand for OTC medications.

What are the primary safety concerns linked to acetaminophen?

Hepatotoxicity and liver failure from overdose remain the chief safety issues, prompting regulatory dose restrictions and increased R&D for safer formulations.

How is innovation influencing the competitive landscape?

Product innovation centers on improved safety, extended-release formats, and combination drugs, helping firms differentiate amid intense generic competition.

References

[1] MarketWatch. (2023). Acetaminophen Market Size, Share & Trends Analysis. https://www.marketwatch.com/
[2] Grand View Research. (2023). Paracetamol (Acetaminophen) Market Analysis. https://www.grandviewresearch.com/
[3] FDA. (2022). Acetaminophen-related dosing guidelines. https://www.fda.gov/
[4] EMA. (2021). Safe use of paracetamol: Regulatory guidelines. https://www.ema.europa.eu/
[5] IQVIA. (2022). Global OTC Market Trends Report. https://www.iqvia.com/